Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shampa Das

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Mbio|January 18, 2024
Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>Nicola Farrington, Vineet Dubey, Adam Johnson, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|November 19, 2013
Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsisPeter Newham, Daniel Ross, Peter Ceuppens, et al.
The Lancet. Digital Health|November 15, 2024
Using digital health technologies to optimise antimicrobial use globallyTimothy M Rawson, Nina Zhu, Ronald Galiwango, et al.
The Journal of Antimicrobial Chemotherapy|September 24, 2025
Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosisChristopher A Darlow, Nicola Farrington, Anne-Grete Märtson, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2019
Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative InfectionsLaura McEntee, Adam Johnson, Nicola Farrington, et al.
Antimicrobial Agents and Chemotherapy|April 8, 2020
Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>Adam Johnson, Laura McEntee, Nicola Farrington, et al.
Clinical and Translational Science|September 18, 2018
Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient SubgroupsJianguo Li, Mark Lovern, Michelle L Green, et al.
Nature|August 2, 2003
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppressionCarola A Neumann, Daniela S Krause, Christopher V Carman, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2020
Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing <i>Enterobacteriaceae</i>Shampa Das, Adam Johnson, Laura McEntee, et al.
The Journal of Antimicrobial Chemotherapy|January 13, 2025
Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driverSanne van den Berg, Marie G L Attwood, Pippa Griffin, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Mbio|January 18, 2024
Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>Nicola Farrington, Vineet Dubey, Adam Johnson, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|November 19, 2013
Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsisPeter Newham, Daniel Ross, Peter Ceuppens, et al.
The Lancet. Digital Health|November 15, 2024
Using digital health technologies to optimise antimicrobial use globallyTimothy M Rawson, Nina Zhu, Ronald Galiwango, et al.
The Journal of Antimicrobial Chemotherapy|September 24, 2025
Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosisChristopher A Darlow, Nicola Farrington, Anne-Grete Märtson, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2019
Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative InfectionsLaura McEntee, Adam Johnson, Nicola Farrington, et al.
Antimicrobial Agents and Chemotherapy|April 8, 2020
Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>Adam Johnson, Laura McEntee, Nicola Farrington, et al.
Clinical and Translational Science|September 18, 2018
Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient SubgroupsJianguo Li, Mark Lovern, Michelle L Green, et al.
Nature|August 2, 2003
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppressionCarola A Neumann, Daniela S Krause, Christopher V Carman, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2020
Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing <i>Enterobacteriaceae</i>Shampa Das, Adam Johnson, Laura McEntee, et al.
The Journal of Antimicrobial Chemotherapy|January 13, 2025
Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driverSanne van den Berg, Marie G L Attwood, Pippa Griffin, et al.
Pageof 6